MDCX Overview

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Wall Street analysts forecast MDCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDCX is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Medicus Pharma Ltd revenue for the last quarter amounts to -6.71M USD, increased 187.41

Medicus Pharma Ltd. EPS for the last quarter amounts to -6757829.00 USD, decreased

Medicus Pharma Ltd (MDCX) has 12 emplpoyees as of March 26 2026.

Today MDCX has the market capitalization of 12.62M USD.